Welcome to EnVivo Pharmaceuticals

		Home \| Company \| Our Team \| Programs \| Publications \| News & Events

EnVivo is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders, currently focusing on Alzheimer’s disease, and Schizophrenia. The company’s lead programs include a Nicotinic Acetylcholine Receptor Agonist Program for cognitive enhancement in Alzheimer’s disease and Schizophrenia, a Histone Deacetylase (HDAC) Inhibitor Program for cognitive enhancement in Alzheimer’s disease, a Gamma Secretase Modulator (GSM) Program for disease modifying treatment of Alzheimer’s disease and a Phospho-Diesterase 10 (PDE10) Program for Schizophrenia.

EnVivo News & Events

	EnVivo Pharmaceuticals announced today that it has initiated a clinical safety and biomarker study of its alpha-7 nicotinic agonist (EVP-6124) in Schizophrenia patients chronically treated with atypical antipsychotic medications.



	Montreal, Quebec and Watertown, MA. February 6, 2008 - MethylGene Inc. (TSX:MYG) and EnVivo Pharmaceuticals today announced that MethylGene has exercised its right to opt-out of further funding in its collaboration with EnVivo signed in February 2005.